The company has reported a total income of Rs.701.89 crores during the period ended June 30, 2021, as compared to Rs.921.54 crores during the period ended March 31, 2021. The company had reported a total income of Rs 794.10 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.(205.2) crores for the period ended June 30, 2021, as against net profit / (loss) of Rs.46.08 crores for the period ended March 31, 2021. The company had reported a net profit/(loss), of Rs 103.56 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.(22.88) for the period ended June 30, 2021, as compared to Rs.5.14 for the period ended March 31, 2021. The EPS for the period ended June 30, 2020, stood at Rs 11.56.

Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, "Q1FY22 has been an unprecedented quarter for Strides amidst multiple macro headwinds from the recent wave of Covid-19. This has led to significant disruptions both on the demand and supply sides. The above headwinds have resulted in the company reporting an operating loss for the first time. While we are witnessing near term challenges due to price erosions, we are taking many actions to adapt to the new market realities.’’

He further added, ``While the Other Regulated Markets delivered a weak quarter led by a significant drop in prescriptions, price challenges in key markets and supply spill owing to Covid-19 impact at our manufacturing sites, our order book continues to remain robust and we expect a bounce-back in Q2FY22.’’

The company expects to see a full recovery in H2FY22 driven by growth across all businesses. Ananthanaryaanan  further added, ``we expect to end the year with a 10-15% revenue growth over US $ 215m reported in the US for FY21."